Mohamad Eisa

Dr. Mohamad Eisa

orcid

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2018 in Bioorganic Chemistry
Verified
Journal Article
Closed access
MAMahmoud S. Abdelbaset
Mahmoud S. Abdelbaset
GAGamal El-Din A Abuo-Rahma
Gamal El-Din A Abuo-Rahma
MAMostafa H. Abdelrahman
Mostafa H. Abdelrahman
MEMohamad Eisa
Mohamad Eisa
BYBahaa G.M. Youssif
Bahaa G.M. Youssif
MAMohamed Abdel-Aziz
Mohamed Abdel-Aziz

1 March 2019 in Bioorganic & Medicinal Chemistry
Verified
Journal Article
Closed access
MAMahmoud S. Abdelbaset
Mahmoud S. Abdelbaset
MAMohamed Abdel-Aziz
Mohamed Abdel-Aziz
MEMohamad Eisa
Mohamad Eisa
MAMostafa H. Abdelrahman
Mostafa H. Abdelrahman
Syed Nasir Abbas BukhariSyed Nasir Abbas Bukhari
Syed Nasir Abbas Bukhari
GAGamal El-Din A Abuo-Rahma
Gamal El-Din A Abuo-Rahma

18 August 2021 in Molecules
Verified
Journal Article
Open access
PDF file
MEMohamad Eisa
Mohamad Eisa
Ashraf A. AlyAshraf A. Aly
Ashraf A. Aly
LALamiaa Abdelhaleem
Lamiaa Abdelhaleem
MAMohammed Alshammari
Mohammed Alshammari
SBStefan Bräse
Stefan Bräse
Pyrazoles are considered privileged scaffolds in medicinal chemistry. Previous reviews have discussed the importance of pyrazoles and their biological activities; however, few have dealt with the chemistry and the biology of heteroannulated derivatives. Therefore, we focused our attention on recent topics, up until 2020, for the synthesis of pyrazoles, their heteroannulated derivatives, and their applications as biologically active moieties. Moreover, we focused on traditional procedures used in the synthesis of pyrazoles.

1 December 2020 in Bioorganic Chemistry
Verified
Journal Article
Closed access
MRMohamed Ramadan
Mohamed Ramadan
MEMohamad Eisa
Mohamad Eisa
YEYaseen Elshaier
Yaseen Elshaier
BYBahaa G. M. Youssif
Bahaa G. M. Youssif
ABAlan B. Brown
Alan B. Brown
Ashraf A. AlyAshraf A. Aly
Ashraf A. Aly

8 May 2023 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
SESamar El-Kalyoubi
Samar El-Kalyoubi
HGHesham Gomaa
Hesham Gomaa
EAElshimaa Abdelhafez
Elshimaa Abdelhafez
MEMohamad Eisa
Mohamad Eisa
FAFatimah Abdulaziz Agili
Fatimah Abdulaziz Agili
BYBahaa G. M. Youssif
Bahaa G. M. Youssif
The investigation of novel EGFR and BRAFV600E dual inhibitors is intended to serve as targeted cancer treatment. Two sets of purine/pteridine-based derivatives were designed and synthesized as EGFR/BRAFV600E dual inhibitors. The majority of the compounds exhibited promising antiproliferative activity on the cancer cell lines tested. Compounds 5a, 5e, and 7e of purine-based and pteridine-based scaffolds were identified as the most potent hits in anti-proliferative screening, with GI50 values of 38 nM, 46 nM, and 44 nM, respectively. Compounds 5a, 5e, and 7e demonstrated promising EGFR inhibitory activity, with IC50 values of 87 nM, 98 nM, and 92 nM, respectively, when compared to erlotinib’s IC50 value of 80 nM. According to the results of the BRAFV600E inhibitory assay, BRAFV600E may not be a viable target for this class of organic compounds. Finally, molecular docking studies were carried out at the EGFR and BRAFV600E active sites to suggest possible binding modes.

26 October 2021 in Molecular Diversity
Verified
Journal Article
Closed access
PDF file
YEYaseen Elshaier
Yaseen Elshaier
Ashraf A. AlyAshraf A. Aly
Ashraf A. Aly
MEMohamed Abd El-Aziz
Mohamed Abd El-Aziz
HSHazem Salama
Hazem Salama
ABAlan B. Brown
Alan B. Brown
MEMohamad Eisa
Mohamad Eisa